Evaluation du site takeda.com
Takeda Pharmaceuticals: Global Homepage
Généré le 04 Mars 2026 10:15
Vieilles statistiques? UPDATE !
Le score est de 53/100
Optimisation du contenu
Titre
Takeda Pharmaceuticals: Global Homepage
Longueur : 39
Parfait, votre titre contient entre 10 et 70 caractères.
Description
Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
Longueur : 131
Génial, votre balise META description contient entre 70 et 160 caractères.
Mots-clefs
Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.
Propriétés Open Graph
Bien, cette page profite des balises META Open Graph.
| Propriété | Contenu |
|---|---|
| title | Takeda Pharmaceuticals: Global Homepage |
| description | Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future. |
| url | https://www.takeda.com/ |
| locale | en |
| image | http://assets-dam.takeda.com/image/upload/v1683892920/Global/OG%20Logo.jpg |
| image:secure_url | https://assets-dam.takeda.com/image/upload/v1683892920/Global/OG%20Logo.jpg |
| image:width | 1200 |
| image:height | 627 |
| image:type | image |
| image:alt | Takeda Pharmaceuticals: Global Homepage |
| type | website |
Niveaux de titre
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 5 | 14 | 0 | 0 | 0 |
- [H1] Takeda Pharmaceuticals: Global Homepage
- [H2] Expanding access to hereditary angioedema care in Vietnam
- [H2] Recent News
- [H2] Better Health, Brighter Future
- [H2] Our Areas of Focus
- [H2] Sign up for investors newsletter
- [H3] Takeda - Global
- [H3] Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
- [H3] Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
- [H3] U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- [H3] Takeda Reports Third-Quarter FY2025 Results – Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind – Progressing Toward Three Transformative Launches Ahead
- [H3] Join Us
- [H3] Investors
- [H3] R&D
- [H3] Gastrointestinal and Inflammation
- [H3] Rare Diseases
- [H3] Plasma-Derived Therapies
- [H3] Oncology
- [H3] Neuroscience
- [H3] Vaccines
Images
Nous avons trouvé 6 image(s) sur cette page Web.
Bien, la plupart ou la totalité de vos images possèdent un attribut alt
Ratio texte/HTML
Ratio : 2%
le ratio de cette page texte/HTML est au-dessous de 15 pour cent, ce qui signifie que votre site manque de contenu textuel.
Flash
Parfait, aucun contenu FLASH n'a été détecté sur cette page.
Iframe
Génial, il n'y a pas d'Iframes détectés sur cette page.
Liens
Réécriture d'URLs
Bien. Vos liens sont optimisés!
Tiret bas dans les URLs
Parfait! Aucuns soulignements détectés dans vos URLs.
Liens dans la page
Nous avons trouvé un total de 134 lien(s) dont 0 lien(s) vers des fichiers
| Texte d'ancre | Type | Juice |
|---|---|---|
| Our Company | Interne | Passing Juice |
| Leadership | Interne | Passing Juice |
| Sustainability Approach | Interne | Passing Juice |
| Access to Medicines | Interne | Passing Juice |
| Sustainability Disclosures | Interne | Passing Juice |
| Ethics | Interne | Passing Juice |
| Transparency Disclosures | Interne | Passing Juice |
| Positions | Interne | Passing Juice |
| Corporate Giving | Interne | Passing Juice |
| Governance Strategy | Interne | Passing Juice |
| Governance Structure | Interne | Passing Juice |
| Charters and Reports | Interne | Passing Juice |
| Areas of Focus | Interne | Passing Juice |
| Research and Development | Interne | Passing Juice |
| Pipeline | Interne | Passing Juice |
| Our Products | Interne | Passing Juice |
| Manufacturing | Interne | Passing Juice |
| Suppliers | Interne | Passing Juice |
| Clinical Trials | Interne | Passing Juice |
| Our Stories | Interne | Passing Juice |
| Press Releases | Interne | Passing Juice |
| Statements | Interne | Passing Juice |
| Media Resources | Interne | Passing Juice |
| Overview | Interne | Passing Juice |
| Financial Results | Interne | Passing Juice |
| Investor Events | Interne | Passing Juice |
| Investor Contact | Interne | Passing Juice |
| Careers | Interne | Passing Juice |
| Leadership | Interne | Passing Juice |
| Sustainability Approach | Interne | Passing Juice |
| Access to Medicines | Interne | Passing Juice |
| Ethics | Interne | Passing Juice |
| Corporate Giving | Interne | Passing Juice |
| Governance Structure | Interne | Passing Juice |
| Charters and Reports | Interne | Passing Juice |
| Research and Development | Interne | Passing Juice |
| Pipeline | Interne | Passing Juice |
| Our Products | Interne | Passing Juice |
| Manufacturing | Interne | Passing Juice |
| Suppliers | Interne | Passing Juice |
| Clinical Trials | Interne | Passing Juice |
| Press Releases | Interne | Passing Juice |
| Statements | Interne | Passing Juice |
| Media Resources | Interne | Passing Juice |
| Overview | Interne | Passing Juice |
| Financial Results | Interne | Passing Juice |
| Investor Events | Interne | Passing Juice |
| Investor Contact | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Japanese | Interne | Passing Juice |
| English | Interne | Passing Juice |
| French | Interne | Passing Juice |
| Arabic | Interne | Passing Juice |
| Spanish | Interne | Passing Juice |
| English | Interne | Passing Juice |
| German | Interne | Passing Juice |
| Russian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| French | Interne | Passing Juice |
| Dutch | Interne | Passing Juice |
| Bosnian | Interne | Passing Juice |
| Portuguese | Interne | Passing Juice |
| Bulgarian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| French | Interne | Passing Juice |
| Spanish | Interne | Passing Juice |
| Chinese | Interne | Passing Juice |
| Spanish | Interne | Passing Juice |
| Croatian | Interne | Passing Juice |
| Czech | Interne | Passing Juice |
| Danish | Interne | Passing Juice |
| Spanish | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Arabic | Interne | Passing Juice |
| Estonian | Interne | Passing Juice |
| Finnish | Interne | Passing Juice |
| French | Interne | Passing Juice |
| German | Interne | Passing Juice |
| Greek | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Chinese | Interne | Passing Juice |
| Hungarian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Indonesian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Hebrew | Interne | Passing Juice |
| Italian | Interne | Passing Juice |
| Kazakh | Interne | Passing Juice |
| Russian | Interne | Passing Juice |
| Korean | Interne | Passing Juice |
| Latvian | Interne | Passing Juice |
| Lithuanian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Spanish | Interne | Passing Juice |
| Dutch | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Norweigan | Interne | Passing Juice |
| Spanish | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Polish | Interne | Passing Juice |
| Portuguese | Interne | Passing Juice |
| Romanian | Interne | Passing Juice |
| Russian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Arabic | Interne | Passing Juice |
| Serbian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Slovak | Interne | Passing Juice |
| Slovenian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Spanish | Interne | Passing Juice |
| Swedish | Interne | Passing Juice |
| German | Interne | Passing Juice |
| French | Interne | Passing Juice |
| Chinese | Interne | Passing Juice |
| Thai | Interne | Passing Juice |
| Turkish | Interne | Passing Juice |
| Ukrainian | Interne | Passing Juice |
| English | Interne | Passing Juice |
| Arabic | Interne | Passing Juice |
| English | Interne | Passing Juice |
| English | Interne | Passing Juice |
| English | Interne | Passing Juice |
| - | Interne | Passing Juice |
| Locations | Interne | Passing Juice |
| Contact us | Interne | Passing Juice |
| Careers | Interne | Passing Juice |
| Financial Highlights | Interne | Passing Juice |
| HCPs | Interne | Passing Juice |
| Patients | Interne | Passing Juice |
| Terms and Conditions | Interne | Passing Juice |
| Privacy Notice | Interne | Passing Juice |
| Cookie Policy | Interne | Passing Juice |
| Accessibility Statement | Interne | Passing Juice |
Mots-clefs
Nuage de mots-clefs
arabic more patients diseases drug french takeda corporate english spanish
Cohérence des mots-clefs
| Mot-clef | Contenu | Titre | Mots-clefs | Description | Niveaux de titre |
|---|---|---|---|---|---|
| english | 38 |  |
|
|
|
| spanish | 14 | |
|
|
|
| diseases | 11 | |
|
|
 |
| french | 10 | |
|
|
|
| takeda | 9 | |
|
|
|
Ergonomie
Url
Domaine : takeda.com
Longueur : 10
Favicon
Génial, votre site web dispose d'un favicon.
Imprimabilité
Aucun style CSS pour optimiser l'impression n'a pu être trouvé.
Langue
Bien. Votre langue est : en.
Dublin Core
Cette page ne profite pas des métadonnées Dublin Core.
Document
Doctype
HTML 5
Encodage
Parfait. Votre charset est UTF-8.
Validité W3C
Erreurs : 0
Avertissements : 0
E-mail confidentialité
Attention! Au moins une adresse e-mail a été trouvée en texte clair. Utilisez une protection anti-spam gratuite pour cacher vos e-mails aux spammeurs.
HTML obsolètes
Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.
Astuces vitesse
|
Excellent, votre site n'utilise pas de tableaux imbriqués. |
|
Mauvais, votre site web utilise des styles css inline. |
|
Mauvais, votre site web contient trop de fichiers CSS (plus de 4). |
|
Mauvais, votre site web contient trop de fichiers javascript (plus de 6). |
|
Parfait : votre site tire parti de gzip. |
Mobile
Optimisation mobile
|
Icône Apple |
|
Méta tags viewport |
|
Contenu FLASH |
Optimisation
Sitemap XML
Votre site web dispose d’une sitemap XML, ce qui est optimal.
| https://www.takeda.com/sitemap.xml |
Robots.txt
https://takeda.com/robots.txt
Votre site dispose d’un fichier robots.txt, ce qui est optimal.
Mesures d'audience
Manquant
Nous n'avons trouvé aucun outil d'analytics sur ce site.
Un outil de mesure d'audience vous permet d'analyser l’activité des visiteurs sur votre site. Vous devriez installer au moins un outil Analytics. Il est souvent utile d’en rajouter un second, afin de confirmer les résultats du premier.
PageSpeed Insights
Dispositif
Les catégories
Free SEO Testing Tool
Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web